LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Clinical trial NCT07186101 · RECRUITING

Trial details

NCT number: NCT07186101
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ulcerative Colitis

Start date: 2025-11-10
Primary completion: 2027-05-01
Enrollment: 252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.